Madrigal Pharmaceuticals
MDGL
140 hedge funds and large institutions have $1.2B invested in Madrigal Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 45 increasing their positions, 46 reducing their positions, and 25 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
19% more capital invested
Capital invested by funds: $1.01B → $1.2B (+$188M)
1.7% more ownership
Funds ownership: 69.92% → 71.62% (+1.7%)
2% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 46
3% less funds holding
Funds holding: 144 → 140 (-4)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
41% less call options, than puts
Call options by funds: $9.34M | Put options by funds: $15.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$28.9M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$24.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$16.2M |
| 4 |
State Street
Boston,
Massachusetts
|
+$14.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$35.4M |
| 2 |
AC
Armistice Capital
New York
|
-$12.3M |
| 3 |
Goldman Sachs
New York
|
-$4.8M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.46M |
| 5 |
ACM
Altium Capital Management
New York
|
-$2.03M |
MDGL Hedge Fund Activity: Q1 2022 in Review
140 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2022, worth a combined $1.2B — up 19% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of MDGL and 21 opened new positions — a net loss of 4 holders — while 46 trimmed existing stakes and 45 added.
The largest buyer was Federated Hermes, opening a new position worth an estimated $28.9M. The largest seller was Wellington Management Group, cutting an estimated $35.4M.
- 140 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2022, down from 144 in Q4 2021.
- Funds reported $1.2B of Madrigal Pharmaceuticals stock for Q1 2022, up 19% quarter-over-quarter.
- 21 funds opened new Madrigal Pharmaceuticals positions in Q1 2022 and 25 closed out, a net change of -4 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2022 was Federated Hermes, an estimated $28.9M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2022 was Wellington Management Group, an estimated $35.4M sold.
Based on aggregated 13F filings for Q1 2022.